Experimental estrogen-induced hyperprolactinemia results in bone-related hearing loss in the guinea pig

American Journal of Physiology - Endocrinology and Metabolism

Volumn 293, Issue 5, 2007, Pages

  Horner, Kathleen C ^a,c   Cazals, Yves ^a   Guieu, Régis ^a   Lenoir, Marc ^b   Sauze, Nicole ^a  

^a CNRS   (France)

^b INSERM   (France)

^c University of Mediterranée   (France)

Author keywords

Deafness; Estrogen; Hormones; Osteoprotegerin; Prolactin

Indexed keywords

ESTROGEN; NEUROLEPTIC AGENT;

AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUDIOGRAPHY; BONE MALFORMATION; CELL DAMAGE; COCHLEA; CONTROLLED STUDY; CYTOPATHOLOGY; EXPERIMENTAL STUDY; FEMALE; FISCHER 344 RAT; FROZEN SECTION; GUINEA PIG; HAIR CELL; HEARING LOSS; HYPERPROLACTINEMIA; INNER EAR; MALE; MICROSCOPE; MICROSCOPY; NONHUMAN; PREGNANCY; PRIORITY JOURNAL; RAT; SCANNING ELECTRON MICROSCOPY; STEREOCILIUM; STRESS; STRIA VASCULARIS;

ANIMALS; AUDIOMETRY; COCHLEA; ESTRADIOL; EVOKED POTENTIALS, AUDITORY, BRAIN STEM; FEMALE; GUINEA PIGS; HAIR CELLS, AUDITORY; HEARING LOSS, SENSORINEURAL; HYPERPROLACTINEMIA; MALE; MICROSCOPY, ELECTRON, SCANNING; PROLACTIN; RATS; RATS, INBRED F344;

EID: 36148992197     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00279.2007     Document Type: Article

References (98)

1. Abraham G, Halbreich U, Friedman RH, Josiassen RC. Bone mineral density and prolactin associations in patients with chronic schizophrenia. Schizophr Res 59: 17-18, 2003.
2. Akesson A, Vahter M, Berglund M, Eklof T, Bremme K, Bjellerup P. Bone turnover from early pregnancy to postweaning. Acta Obstet Gynecol Scand 83: 1049-1055, 2004.
3. Arita J, Kimura F. Direct inhibitory effect of long term estradiol treatment on dopamine synthesis in tuberoinfundibular dopaminergic neurons: in vitro studies using hypothalamic slices. Endocrinology 121: 692-698, 1987.
4. Baranowska B, Wolinska-Witort E, Bik W, Baranowska-Bik A, Martynska L, Chmielowska M. Evaluation of neuroendocrine status in longevity. Neurobiol Aging 28: 774-783, 2007.
5. Ben-Jonathan N, Hnasko R. Dopamine as a prolactin (PRL) inhibitor. Endocr Rev 22: 724-763, 2001.
6. Biller BM, Luciano A, Crosignani PG, Molitch M, Olive D, Rebar R, Sanfilippo J, Webster J, Zacur H. Guidelines for the diagnosis and treatment of hyperprolactinemia. J Reprod Med 44: 1075-1084, 1999.
7. Bittar RS, Cruz OL, Lorenzi MC, Marone SA, Miniti A. Morphological and functional study of the cochlea after administration of estrogen and progesterone in the guinea pig. Int Tinnitus J 7: 41-45, 2001.
8. Blackman MR, Kowatch MA, Wehmann RE, Harman SM. Basal serum prolactin levels and prolactin responses to constant infusions of thyrotropin releasing hormone in healthy aging men. J Gerontol 41: 699-705, 1986.
9. Blagoveshchenskaia NS, Leushkina LN. [Otoneurological symptomatology in tumors of the hypophysis with marked extrasellar growth]. Zh Vopr Neirokhir Im N N Burdenko: 24-28, 1988.
10. Bole-Feysot C, Goffin V, Edery M, Binart N, Kelly PA. Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev 19: 225-268, 1998.
11. Brookler KH, Glenn MB. Meniere's syndrome: an approach to therapy. Ear Nose Throat J 74: 534-538, 540, 542, 1995.
12. Canlon B, Meltser I, Johansson P, Tahera Y. Glucocorticoid receptors modulate auditory sensitivity to acoustic trauma. Hear Res 226: 61-69, 2007.
13. Carbajal ME, Vitale ML. The cortical actin cytoskeleton of lactotropes as an intracellular target for the control of prolactin secretion. Endocrinology 138: 5374-5384, 1997.
14. Carlsson A. Antipsychotic drugs, neurotransmitters, schizophrenia. Am J Psychiatry 135: 165-173, 1978.
15. Chole RA, McKenna M. Pathophysiology of otosclerosis. Otol Neurotol 22: 249-257, 2001.
16. Ciftci E, Erden I, Akyar S. Brucellosis of the pituitary region. MRI Neuroradiol 40: 383-384, 1998.
17. Clark K, Sowers MR, Wallace RB, Jannausch ML, Lemke J, Anderson CV. Age-related hearing loss and bone mass in a population of rural women aged 60 to 85 years. Ann Epidemiol 5: 8-14, 1995.
18. Clayton AE, Mikulec AA, Mikulec KH, Merchant SN, McKenna MJ. Association between osteoporosis and otosclerosis in women. J Laryngol Otol 118: 617-621, 2004.
19. Clifton KH, Meyer RK. Mechanism of anterior pituitary tumor induction by estrogen. Anat Rec 125: 65-81, 1956.
20. Coleman JR, Campbell D, Cooper WA, Welsh MG, Moyer J. Auditory brainstem responses after ovariectomy and estrogen replacement in rat. Hear Res 80: 209-215, 1994.
21. Connolly ES Jr, Winfree CJ, Carmel PW. Giant posterior fossa cystic craniopharyngiomas presenting with hearing loss. Report of three cases and review of the literature. Surg Neurol 47: 291-299, 1997.
22. Cooper WA, Ross KC, Coleman JR. Estrogen treatment and age effects on auditory brainstem responses in the post-breeding Long-Evans rat. Audiology 38: 7-12, 1999.
23. Coss D, Yang L, Kuo CB, Xu X, Luben RA, Walker AM. Effects of prolactin on osteoblast alkaline phosphatase and bone formation in the developing rat. Am J Physiol Endocrinol Metab 279: E1216-E1225, 2000.
24. Craven AJ, Nixon AJ, Ashby MG, Ormandy CJ, Blazek K, Wilkins RJ, Pearson AJ. Prolactin delays hair regrowth in mice. J Endocrinol 191: 415-425, 2006.
25. Cross NA, Hillman LS, Allen SH, Krause GF, Vieira NE. Calcium homeostasis and bone metabolism during pregnancy, lactation, and post-weaning: a longitudinal study. Am J Clin Nutr 61: 514-523, 1995.
26. Declau F, Van Spaendonck M, Timmermans JP, Michaels L, Liang J, Qiu JP, Van de Heyning P. Prevalence of otosclerosis in an unselected series of temporal bones. Otol Neurotol 22: 596-602, 2001.
27. Dominguez Ugidos LJ, Martinez Subias J, Urpegui Garcia A, Sancho Serrano E, Alfonso Collado JI, Valles Varela H. [Invasive giant prolactinoma.] Acta Otorrinolaringol Esp 49: 156-158, 1998.
28. Emiliano AB, Fudge JL. From galactorrhea to osteopenia: rethinking serotonin-prolactin interactions. Neuropsychopharmacology 29: 833-846, 2004.
29. Esquifino AI, Cano P, Jimenez V, Reyes Toso CF, Cardinali DP. Changes of prolactin regulatory mechanisms in aging: 24-h rhythms of serum prolactin and median eminence and adenohypophysial concentration of dopamine, serotonin, gamma-aminobutyric acid, taurine and somatostatin in young and aged rats. Exp Gerontol 39: 45-52, 2004.
30. Falkenius-Schmidt K, Rydmarker S, Horner KC. Hyperprolactinemia in some Meniere patients even in the absence of incapacitating vertigo. Hear Res 203: 154-158, 2005.
31. Fay RR. Comparative psychoacoustics. Hear Res 34: 295-305, 1988.
32. Foitzik K, Krause K, Conrad F, Nakamura M, Funk W, Paus R. Human scalp hair follicles are both a target and a source of prolactin, which serves as an autocrine and/or paracrine promoter of apoptosis-driven hair follicle regression. Am J Pathol 168: 748-756, 2006.
33. Freeman ME, Kanyicska B, Lerant A, Nagy G. Prolactin: structure, function, and regulation of secretion. Physiol Rev 80: 1523-1631, 2000.
34. Gao Q, Mezei G, Nie Y, Rao Y, Choi CS, Bechmann I, Leranth C, Toran-Allerand D, Priest CA, Roberts JL, Gao XB, Mobbs C, Shulman GI, Diano S, Horvath TL. Anorectic estrogen mimics leptin's effect on the rewiring of melanocortin cells and Stat3 signaling in obese animals. Nat Med 13: 89-94, 2007.
35. Geary N. Estradiol, CCK and satiation. Peptides 22: 1251-1263, 2001.
36. Gordon MA. The genetics of otosclerosis: a review. Am J Otol 10: 426-438, 1989.
37. Gordon-Salant S. Hearing loss and aging: new research findings and clinical implications. J Rehabil Res Dev 42: 9-24, 2005.
38. Gristwood RE, Venables WN. Pregnancy and otosclerosis. Clin Otolaryngol 8: 205-210, 1983.
39. Guimaraes P, Frisina ST, Mapes F, Tadros SF, Frisina DR, Frisina RD. Progestin negatively affects hearing in aged women. Proc Natl Acad Sci USA 103: 14246-14249, 2006.
40. Guimaraes P, Zhu X, Cannon T, Kim S, Frisina RD. Sex differences in distortion product otoacoustic emissions as a function of age in CBA mice. Hear Res 192: 83-89, 2004.
41. Halbreich U, Kahn LS. Hyperprolactinemia and schizophrenia: mechanisms and clinical aspects. J Psychiatr Pract 9: 344-353, 2003.
42. Halbreich U, Kinon BJ, Gilmore JA, Kahn LS. Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology 28, Suppl 1: 53-67, 2003.
43. Halbreich U, Rojansky N, Palter S, Hreshchyshyn M, Kreeger J, Bakhai Y, Rosan R. Decreased bone mineral density in medicated psychiatric patients. Psychosom Med 57: 485-491, 1995.
44. Hanna GS. Sudden deafness and the contraceptive pill. J Laryngol Otol 100: 701-706, 1986.
45. Hebert S, Paiement P, Lupien SJ. A physiological correlate for the intolerance to both internal and external sounds. Hear Res 190: 1-9, 2004.
46. Helzner EP, Cauley JA, Pratt SR, Wisniewski SR, Talbott EO, Zmuda JM, Harris TB, Rubin SM, Taaffe DR, Tylavsky FA, Newman AB. Hearing sensitivity and bone mineral density in older adults: the Health, Aging and Body Composition Study. Osteoporos Int 16: 1675-1682, 2005.
47. Horner KC, Cazals Y. Stress hormones in Meniere's disease and acoustic neuroma. Brain Res Bull 66: 1-8, 2005.
48. Horner KC, Cazals Y, Guillhaume A. Round window cochlear microphonics and atrophy of short and middle stereocilia on outer hair cells in hydropic cochleas in the guinea pig. In: Cochlear Mechanisms, edited by Wilson JP and Kemp DT. London: Plenum, 1989, p. 207-215.
49. Horner KC, Guieu R, Magnan J, Chays A, Cazals Y. Prolactinoma in some Meniere's patients - is stress involved? Neuropsychopharmacology 26: 135-138, 2002.
50. Horner KC, Guilhaume A, Cazals Y. Atrophy of middle and short stereocilia on outer hair cells of guinea pig cochleas with experimentally induced hydrops. Hear Res 32: 41-48, 1988.
51. Hultcrantz M, Simonoska R, Stenberg AE. Estrogen and hearing: a summary of recent investigations. Acta Otolaryngol (Stockh) 126: 10-14, 2006.
52. Ismail MS, Serour GI, Torsten U, Weitzel H, Berlien HP. Elevated serum prolactin level with high-dose estrogen contraceptive pills. Eur J Contracept Reprod Health Care 3: 45-50, 1998.
53. Kim SH, Kang BM, Chae HD, Kim CH. The association between serum estradiol level and hearing sensitivity in postmenopausal women. Obstet Gynecol 99: 726-730, 2002.
54. Klibanski A, Neer RM, Beitins IZ, Ridgway EC, Zervas NT, McArthur JW. Decreased bone density in hyperprolactinemic women. N Engl J Med 303: 1511-1514, 1980.
55. 45Ca uptake, calcium deposit, and calcium resorption in weaned, young, and mature rats. Can J Physiol Pharmacol 74: 1157-1165, 1996.
56. Lee JH, Marcus DC. Estrogen acutely inhibits ion transport by isolated stria vascularis. Hear Res 158: 123-130, 2001.
57. Lin JY, Mai LM, Pan JT. Effects of systemic administration of 6-hydroxydopamine, 6-hydroxydopa and 1-methyl-4-phenyl-1,2,3,6- tetrahydroxypyridine (MPTP) on tuberoinfundibular dopaminergic neurons in the rat. Brain Res 624: 126-130, 1993.
58. Lopez JM, Gonzalez G, Reyes V, Campino C, Diaz S. Bone turnover and density in healthy women during breastfeeding and after weaning. Osteoporos Int 6: 153-159, 1996.
59. Machado LJ, Reis AM, Coimbra CC. Evidence of angiotensin II involvement in prolactin secretion in response to hemorrhage in adrenodemedullated and guanethidine-treated rats. Eur J Endocrinol 146: 439-446, 2002.
60. McKenna MJ, Kristiansen AG. Molecular biology of otosclerosis. Adv Otorhinolaryngol 65: 68-74, 2007.
61. McKenna MJ, Nguyen-Huynh AT, Kristiansen AG. Association of otosclerosis with Sp1 binding site polymorphism in COL1A1 gene: evidence for a shared genetic etiology with osteoporosis. Otol Neurotol 25: 447-450, 2004.
62. Meaney AM, Smith S, Howes OD, O'Brien M, Murray RM, O'Keane V. Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. Br J Psychiatry 184: 503-508, 2004.
63. Meltzer HY, Busch DA, Fang VS. Serum neuroleptic and prolactin levels in schizophrenic patients and clinical response. Psychiatry Res 9: 271-283, 1983.
64. Naidoo U, Goff DC, Klibanski A. Hyperprolactinemia and bone mineral density: the potential impact of antipsychotic agents. Psychoneuroendocrinology 28, Suppl 2: 97-108, 2003.
65. Negishi K, Suzuki T, Masuda Y, Masugi Y, Teramoto A, Ohama E. [Two autopsy cases of primary pituitary carcinoma.] No To Shinkei 40: 491-496, 1988.
66. Nelson W. Some effects of hypophyseal tumors induced by teatment with estrogens. Cancer Res 2: 728, 1942.
67. Nicholas L, Dawkins K, Golden RN. Psychoneuroendocrinology of depression. Prolactin Psychiatr Clin North Am 21: 341-358, 1998.
68. Okulicz G. [Inner ear disturbance following long-term usage of hormonal contraceptives.] Hno 26: 330-334, 1978.
69. Pahuja DN, DeLuca HF. Stimulation of intestinal calcium transport and bone calcium mobilization by prolactin in vitamin D-deficient rats. Science 214: 1038-1039, 1981.
70. Pearson D, Kaur M, San P, Lawson N, Baker P, Hosking D. Recovery of pregnancy mediated bone loss during lactation. Bone 34: 570-578, 2004.
71. Pearson JD, Morrell CH, Gordon-Salant S, Brant LJ, Metter EJ, Klein LL, Fozard JL. Gender differences in a longitudinal study of age-associated hearing loss. J Acoust Soc Am 97: 1196-1205, 1995.
72. Pecins-Thompson M, Bethea CL. RU 486 blocks and fluoxetine augments progesterone-induced prolactin secretion in monkeys. Neuroendocrinology 65: 335-343, 1997.
73. Pitkin RM. Calcium metabolism in pregnancy: a review. Am J Obstet Gynecol 121: 724-737, 1975.
74. Popelar J, Groh D, Mazelova J, Syka J. Cochlear function in young and adult Fischer 344 rats. Hear Res 186: 75-84, 2003.
75. Popelar J, Groh D, Pelanova J, Canlon B, Syka J. Age-related changes in cochlear and brainstem auditory functions in Fischer 344 rats. Neurobiol Aging 27: 490-500, 2006.
76. Riggs BL, Melton LJ 3rd. Involutional osteoporosis. N Engl J Med 314: 1676-1686, 1986.
77. Rolandi E, Magnani G, Sannia A, Barreca T. Evaluation of Prl secretion in elderly subjects. Acta Endocrinol 100: 351-357, 1982.
78. Royster M, Driscoll P, Kelly PA, Freemark M. The prolactin receptor in the fetal rat: cellular localization of messenger ribonucleic acid, immunoreactive protein, and ligand-binding activity and induction of expression in late gestation. Endocrinology 136: 3892-3900, 1995.
79. Rydmarker S, Horner KC. Atrophy of outer hair cell stereocilia and hearing loss in hydropic cochleae. Hear Res 53: 113-122, 1991.
80. Rydmarker S, Horner KC. Morphological changes of hair cell stereocilia and tectorial membrane in guinea pigs with experimentally induced hydrops. Scanning Microsc 4: 705-713, 1990.
81. Sawin CT, Carlson HE, Geller A, Castelli WP, Bacharach P. Serum prolactin and aging: basal values and changes with estrogen use and hypothyroidism. J Gerontol 44: M131-M135, 1989.
82. Schaller B, Kirsch E, Tolnay M, Mindermann T. Symptomatic granular cell tumor of the pituitary gland: case report and review of the literature. Neurosurgery 42: 166-170, 1998.
83. Sellari-Franceschini S, Ravecca F, De Vito A, Berrettini S. [Progressive sensorineural hearing loss in cochlear otosclerosis.] Acta Otorhinolaryngol Ital 18: 59-65, 1998.
84. Shea JJ Jr, Ge X, Orchik DJ. Endolymphatic hydrops associated with otosclerosis. Am J Otol 15: 348-357, 1994.
85. Sherman BE, Chole RA. Effect of chemical sympathectomy with 6-hydroxydopamine on osteoclast activity in the gerbilline middle ear bulla. Otol Neurotol 22: 237-241, 2001.
86. Sherman BE, Chole RA. Effect of pharmacological sympathectomy on osteoclastic activity in the gerbilline auditory bulla in vivo. Ann Otol Rhinol Laryngol 108: 1078-1087, 1999.
87. Sismanis A, Hughes GB, Abedi E. Coexisting otosclerosis and Meniere's disease: a diagnostic and therapeutic dilemma. Laryngoscope 96: 9-13, 1986.
88. Srivastava S, Matsuda M, Hou Z, Bailey JP, Kitazawa R, Herbst MP, Horseman ND. Receptor activator of NF-κB ligand induction via Jak2 and Stat5a in mammary epithelial cells. J Biol Chem 278: 46171-46178, 2003.
89. Steger RW. Age related changes in the control of prolactin secretion in the female rat. Neurobiol Aging 2: 119-123, 1981.
90. Stenberg AE, Wang H, Fish J, Schrott-Fischer A 3rd, Sahlin L, Hultcrantz M. Estrogen receptors in the normal adult and developing human inner ear and in Turner's syndrome. Hear Res 157: 87-92, 2001.
91. Stenberg AE, Wang H, Sahlin L, Hultcrantz M. Mapping of estrogen receptors alpha and beta in the inner ear of mouse and rat. Hear Res 136: 29-34, 1999.
92. Strachan D. Sudden sensorineural deafness and hormone replacement therapy. J Laryngol Otol 110: 1148-1150, 1996.
93. Thompson SK, Zhu X, Frisina RD. Estrogen blockade reduces auditory feedback in CBA mice. Otolaryngol Head Neck Surg 135: 100-105, 2006.
94. Toverud SU, Harper C, Munson PL. Calcium metabolism during lactation: enhanced effects of thyrocalcitonin. Endocrinology 99: 371-378, 1976.
95. Vekemans M, Robyn C. Influence of age on serum prolactin levels in women and men. Br Med J 4: 738-739, 1975.
96. Vessey M, Painter R. Oral contraception and ear disease: findings in a large cohort study. Contraception 63: 61-63, 2001.
97. Williams RF, Gianfortoni JG, Hodgen GD. Hyperprolactinemia induced by an estrogen-progesterone synergy: quantitative and temporal effects of estrogen priming in monkeys. J Clin Endocrinol Metab 60: 126-132, 1985.
98. Zehnder AF, Kristiansen AG, Adams JC, Merchant SN, McKenna MJ. Osteoprotegerin in the inner ear may inhibit bone remodeling in the otic capsule. Laryngoscope 115: 172-177, 2005.